Phaseline

Targets › HLA-DR

HLA-DR: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Nov 2027.

Open in Phaseline: the race on HLA-DR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Parvus TherapeuticsPVT401
pMHC-peptide nanomedicine: iron oxide nanoparticle core surrounded by dextran linked to mu
HLA-DRPhase 1Inflammatory Bowel Disease (IBD)Nov 2027

Conditions

Inflammatory Bowel Disease (IBD) (1)

Modalities

small molecule (1)

Companies

Parvus Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.